Sugi Predict

Sugi Predict / Compounds / SCHEMBL2113202

SCHEMBL2113202

SCHEMBL2113202

Fc1ccc(OCc2ccccc2)c(Br)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.57
▸ RAB9A P51151 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ FFAR1 O14842 1/20 0.50
▸ FFAR4 Q5NUL3 1/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ MAPT P10636 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ LRRK2 Q5S007 1/20 0.48
▸ PTPN1 P18031 3/20 0.47
▸ LMNA P02545 1/20 0.47
▸ HTR1A P08908 1/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ MRGPRX4 Q96LA9 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ TLR9 Q9NR96 1/20 0.45
▸ MAOB P27338 2/20 0.45
▸ LIPE Q05469 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23258912 0.87 FFAR1 (0.49) PKMRAB9ASMN1; SMN2FFAR1FFAR4
SCHEMBL30660563 0.86 FFAR1 (0.65) RAB9ASMN1; SMN2FFAR1FFAR4L3MBTL1
SCHEMBL2577580 0.86 FFAR1 (0.65) RAB9ASMN1; SMN2FFAR1FFAR4L3MBTL1
SCHEMBL16446974 0.86 PKM (0.50) PKMRAB9ASMN1; SMN2FFAR1FFAR4
SCHEMBL2801626 0.83 CYP1A2 (0.54) PKMSMN1; SMN2FFAR1FFAR4MAPT
SCHEMBL30835101 0.82 RAB9A (0.59) RAB9ASMN1; SMN2L3MBTL1MAPK1TDP1
SCHEMBL30719648 0.82 MRGPRX4 (0.53) L3MBTL1MAPTMAPK1TDP1LMNA
SCHEMBL412514 0.82 MRGPRX4 (0.53) L3MBTL1MAPTMAPK1TDP1LMNA
SCHEMBL7898169 0.82 RAB9A (0.59) RAB9ASMN1; SMN2L3MBTL1MAPK1TDP1
SCHEMBL30335518 0.81 KDM1A (0.49) RAB9ASMN1; SMN2FFAR1FFAR4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177539-A1 ER DEGRADERS AND USES THEREOF ASTRAZENECA AB (SE) 2025-06-05 — — US disclosed
US-12122761-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2024-10-22 — — US disclosed
CN-114555592-B 2-Azaspiro [3.4] octane derivatives as M4 agonists 诺华股份有限公司 2024-09-06 — — CN disclosed
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-07-06 — — US disclosed
US-11584759-B2 Macrocyclic kinase inhibitor HITGEN INC. (CN) 2023-02-21 — — US disclosed
US-11584759-B2 Macrocyclic kinase inhibitor HITGEN INC. (CN) 2023-02-21 — — US disclosed
US-11548865-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-01-10 — — US disclosed
EP-4041389-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS Novartis AG (CH) 2022-08-17 — — EP disclosed
EP-3783000-B1 MACROCYCLIC KINASE INHIBITOR HITGEN INC (CN) 2022-07-06 — — EP disclosed
EP-3783000-B1 MACROCYCLIC KINASE INHIBITOR HITGEN INC (CN) 2022-07-06 — — EP disclosed
CN-1867329-A (4-hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivative as estrogenic agents WYETH CORP (US) 2006-11-22 — — CN disclosed
CN-1791572-A Novel compounds ASTRAZENECA AB (SE) 2006-06-21 — — CN disclosed
EP-1611091-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2006-01-04 — — EP disclosed
US-20050256317-A1 Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 — — US disclosed
US-20050209309-A1 Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. 2005-09-22 — — US disclosed
EP-1541578-A1 PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-BETA-D-ALDOHEXOPYRANOSIDES TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-06-15 — — EP disclosed
EP-1528066-A1 ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-05-04 — — EP disclosed
WO-2004089885-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-10-21 — — WO disclosed
EP-0385662-A2 Heterocycles with inhibitory activity of 5-lipoxygenase ZENECA LIMITED (GB) 1990-09-05 — — EP disclosed
EP-0375404-A2 Heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-06-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 PKM 4032/4885RAB9A 1641/4885SMN1; SMN2 2919/4885
US-20250177539-A1 ER DEGRADERS AND USES THEREOF ESR1, ESR2, ESRRA PKM 1717/4885RAB9A 2513/4885SMN1; SMN2 455/4885
US-20050256317-A1 Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides ALDOA, DERA, AKR1D1 PKM 883/4885RAB9A 3457/4885SMN1; SMN2 4810/4885
US-12122761-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 PKM 4032/4885RAB9A 1641/4885SMN1; SMN2 2919/4885
US-11548865-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 PKM 4032/4885RAB9A 1641/4885SMN1; SMN2 2919/4885
US-11584759-B2 Macrocyclic kinase inhibitor MAP3K20, TNK2, NTRK1 PKM 1782/4885RAB9A 1324/4885SMN1; SMN2 1556/4885
US-20050209309-A1 Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same SLC5A2, SLC5A1, UGGT1 PKM 2283/4885RAB9A 2818/4885SMN1; SMN2 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.